Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 5
2007 6
2008 2
2009 3
2010 2
2011 2
2012 3
2013 1
2015 2
2016 6
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy.
Chen YC, Lin AS, Hung YC, Chen KD, Wu CY, Lie CH, Hsiao CC, Chen CJ, Liu SF, Fang WF, Chang JC, Wang TY, Wang YH, Chung YH, Chao TY, Leung SY, Su MC, Lin MC. Chen YC, et al. Among authors: chung yh. Exp Ther Med. 2017 Sep;14(3):2040-2052. doi: 10.3892/etm.2017.4773. Epub 2017 Jul 11. Exp Ther Med. 2017. PMID: 28962123 Free PMC article.
A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases.
Chen YM, Fang YT, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chen YC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Chang YP, Lin MC. Chen YM, et al. Among authors: chung yh. PLoS One. 2016 Dec 8;11(12):e0167923. doi: 10.1371/journal.pone.0167923. eCollection 2016. PLoS One. 2016. PMID: 27930702 Free PMC article.
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC. Chen YM, et al. Among authors: chung yh. BMC Cancer. 2016 Nov 8;16(1):868. doi: 10.1186/s12885-016-2917-6. BMC Cancer. 2016. PMID: 27821111 Free PMC article.
Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chen YC, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC. Chen YM, et al. Among authors: chung yh. Lung Cancer. 2016 Aug;98:99-105. doi: 10.1016/j.lungcan.2016.05.020. Epub 2016 May 31. Lung Cancer. 2016. PMID: 27393514
The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Huang KT, Chen HC, Lin MC. Chen YM, et al. Among authors: chung yh. Lung Cancer. 2016 Mar;93:47-54. doi: 10.1016/j.lungcan.2016.01.001. Epub 2016 Jan 7. Lung Cancer. 2016. PMID: 26898614
Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Lin MC. Chen YM, et al. Among authors: chung yh. PLoS One. 2016 Feb 19;11(2):e0149722. doi: 10.1371/journal.pone.0149722. eCollection 2016. PLoS One. 2016. PMID: 26894507 Free PMC article.
Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Huang KT, Chen HC, Chang YC, Lin MC. Chen YM, et al. Among authors: chung yh. Medicine (Baltimore). 2015 Dec;94(50):e2239. doi: 10.1097/MD.0000000000002239. Medicine (Baltimore). 2015. PMID: 26683939 Free PMC article.
Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Huang KT, Chen HC, Chang YC, Lin MC. Chen YM, et al. Among authors: chung yh. PLoS One. 2015 Aug 27;10(8):e0136252. doi: 10.1371/journal.pone.0136252. eCollection 2015. PLoS One. 2015. PMID: 26313661 Free PMC article.
Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.
Chen YC, Hsiao CC, Chen KD, Hung YC, Wu CY, Lie CH, Liu SF, Sung MT, Chen CJ, Wang TY, Chang JC, Tang P, Fang WF, Wang YH, Chung YH, Chao TY, Leung SY, Su MC, Wang CC, Lin MC. Chen YC, et al. Among authors: chung yh. PLoS One. 2013;8(2):e57053. doi: 10.1371/journal.pone.0057053. Epub 2013 Feb 25. PLoS One. 2013. PMID: 23451142 Free PMC article.
32 results